How many drugs treat Red eye?

Drug Landscape tracks 7 marketed treatments for Red eye (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/red-eye.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Red eye — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Red eye (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Red eye, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Zinc Sulfate	ZINC SULFATE	Am Regent	zinc sulfate		1987-01-01
Miralax	Macrogol	Braintree	Osmotic Laxative [EPC]		1984-01-01
Ocuzolin	tetryzoline	Fougera Pharms	tetryzoline	Adrenergic receptor alpha	1979-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Naphcon Forte	NAPHAZOLINE	Novartis	Non-Standardized Chemical Allergen [EPC]	Alpha-2A adrenergic receptor	1971-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Red eye
Novartis · 2 drugs in Red eye
Am Regent · 1 drug in Red eye
Fougera Pharms · 1 drug in Red eye
Generic (multiple manufacturers) · 1 drug in Red eye
Braintree · 1 drug in Red eye
ANI Pharmaceuticals · 1 drug in Red eye

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Red eye:

Cite this brief

Drug Landscape (2026). Red eye — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/red-eye. Accessed 2026-06-10.

Red eye full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing